Navigation Links
New Arthritis Drug Linked to Increased Risk of Heart Attacks

The new arthritis drug Prexige is said to be linked to an increased risk of heart attacks and strokes and arthritis sufferers have been warned to exercise caution in its use.//

The federal government's Pharmaceutical Benefits Scheme (PBS) will make the drug Prexige (generic name, lumiracoxib) available from Tuesday. The drug is the first COX-2 inhibitor to be marketed in Australia since it was found in 2004 that these group of drugs increased risk of heart attacks and strokes.

Popular arthritis drug Vioxx was taken off shelves while the drug Celebrex was forced to carry warnings about heart disease ever since this revelation was made public in 2004. The National Prescribing Service has released an independent review warning that the evidence of long-term cardiovascular safety of the new drug is limited.

Dr Peter Roush from the National Prescribing Service says that the safer option for patients should be to first try to manage their condition with over-the-counter painkillers.

He said, "People with osteoarthritis should first consider an effective dose of paracetamol and speak with their doctor if they need a medicine to manage the pain. For some people, lumiracoxib may be an appropriate alternative to other medicines in the same class. This medicine has benefits for people at risk of a stomach ulcer, but we don't know everything about its risk to the heart and brain."

COX-2 inhibitors have been non-steroidal anti-inflammatory drugs (NSAIDs) which were developed as an alternative to older NSAIDs like ibuprofen, Voltaren, or naproxen. And studies showed that lumiracoxib caused fewer serious ulcer complications such as bleeding, than ibuprofen or naproxen. He said, "But people who are likely to have stomach trouble should use lumiracoxib with caution, as it does not eliminate the risk of getting an ulcer. There's limited evidence available about the long-term risk to your heart when using this medicine, but we do kn ow you should not use it if you have, or are likely to have, cardiovascular disease."

The medicine is recommended for use for the shortest possible time, ideally when symptoms flare up or before painful activities.


'"/>




Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
3. B Vitamin protects and lowers toxicity of Arthritis Drug
4. FDA Approves New Arthritis Drug, Bextra
5. Risk Of Developing Arthritis
6. Arthritis Drug May Cause Liver Damage
7. Arthritis drug can prolong life
8. New treatment for Rheumatoid Arthritis
9. Important cause of Arthritis
10. Personality Impacts Arthritis
11. New Rheumatoid Arthritis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
(Date:3/24/2017)... ... 2017 , ... The law firm of Enea, Scanlan & Sirignano, LLP, ... resident Lauren C. Enea has joined the firm as an associate attorney. Ms. Enea, ... in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... is very strong with a total of 97 drug candidates. Pharma giant ... are involved in the development of the IPF therapeutics. The IPF pipeline ... stage, 15 are in Phase II stage, 12 are in Phase I ...
(Date:3/24/2017)... Global Ampoules Market report provides ... applications and industry chain structure. The Ampoules market analysis ... competitive landscape analysis, and major regions, development status. ... ... providing 10 company profiles and 183 tables and figures ...
(Date:3/24/2017)... March 24, 2017  GenomeDx Biosciences today announced that ... and Decipher® Prostate Cancer Classifier tests will be presented ... Urology (EAU) Congress held March 24 to 28, 2017 ... EAU Congress is Europe,s largest ... in the urological field. The abstract titled ...
Breaking Medicine Technology: